Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marlene A Dressman

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
American Journal of Therapeutics|February 7, 2015
Absolute Bioavailability of TasimelteonRosarelis Torres, Marlene A Dressman, William G Kramer, et al.
Pharmacotherapy|August 9, 2016
Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake DisordersWilbur P Trey Williams, Dewey E McLin, Marlene A Dressman, et al.
Journal of Clinical Pharmacology|April 9, 2015
Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonistBrian W Ogilvie, Rosarelis Torres, Marlene A Dressman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)Marlene A Dressman, Rachel Malinowski, Lee Anne McLean, et al.
Expert Opinion on Drug Safety|September 23, 2015
Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studiesDamien Leger, Maria-Antonia Quera-Salva, Marie-Françoise Vecchierini, et al.
Cancer Research|May 3, 2003
Gene expression profiling detects gene amplification and differentiates tumor types in breast cancerMarlene A Dressman, Alex Baras, Rachel Malinowski, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
American Journal of Therapeutics|February 7, 2015
Absolute Bioavailability of TasimelteonRosarelis Torres, Marlene A Dressman, William G Kramer, et al.
Pharmacotherapy|August 9, 2016
Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake DisordersWilbur P Trey Williams, Dewey E McLin, Marlene A Dressman, et al.
Journal of Clinical Pharmacology|April 9, 2015
Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonistBrian W Ogilvie, Rosarelis Torres, Marlene A Dressman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)Marlene A Dressman, Rachel Malinowski, Lee Anne McLean, et al.
Expert Opinion on Drug Safety|September 23, 2015
Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studiesDamien Leger, Maria-Antonia Quera-Salva, Marie-Françoise Vecchierini, et al.
Cancer Research|May 3, 2003
Gene expression profiling detects gene amplification and differentiates tumor types in breast cancerMarlene A Dressman, Alex Baras, Rachel Malinowski, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Pageof 1